[SCHEDULE 13G/A] Checkpoint Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Checkpoint Therapeutics received a Schedule 13G/A filing from Beryl Capital and affiliated entities reporting they do not beneficially own any shares of the company's common stock. The filing shows 0 shares held and 0% of the class and explicitly states the reporting persons disclaim beneficial ownership except for any pecuniary interest.

The filing identifies the reporting parties as an investment adviser and related partnerships, confirms the position is reported as "5 percent or less of a class," and includes certifications that the securities were not acquired to influence control. Signatures from Beryl's COO and David A. Witkin are included.

Insights

Financial Analyst

TL;DR: Routine disclosure—Beryl reports zero CKPT holdings; no material change to ownership.

The Schedule 13G/A shows 0 shares and 0% ownership by Beryl Capital, Beryl GP, the Partnership and David A. Witkin. Item 10 certifications state the securities were held in the ordinary course of business and not to influence control. From a market-impact perspective, this filing conveys no change to shareholder composition or voting dynamics and is therefore immaterial to valuation.

Corporate Governance Expert

TL;DR: Filing clarifies reporting relationships and disclaims beneficial ownership; no governance implications.

The statement discloses the reporting entities' relationships (investment adviser, general partner and related partnership) and explicitly disclaims beneficial ownership beyond pecuniary interest. The filing also classifies the position as ownership of 5% or less. Because all reported voting and dispositive powers are 0, there is no indicated intent or ability by these parties to affect corporate control or governance at this time.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Checkpoint Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

162828206

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 162828206

1

Names of Reporting Persons

Beryl Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 162828206

1

Names of Reporting Persons

Beryl Capital Management LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 162828206

1

Names of Reporting Persons

Beryl Capital Partners II LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 162828206

1

Names of Reporting Persons

David A. Witkin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Checkpoint Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 95 SAWYER ROAD SUITE 110 WALTHAM, MA 02453
Item 2.
(a)	Name of person filing: Beryl Capital Management LLC, a Delaware limited liability company ("Beryl") Beryl Capital Management LP, a Delaware limited partnership ("Beryl GP") Beryl Capital Partners II LP, a Delaware limited partnership (the "Partnership") David A. Witkin Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any Common Stock covered by this Schedule 13G.
(b)	Address or principal business office or, if none, residence: 225 Avenue I, Suite 205 Redondo Beach, CA 90277
(c)	Citizenship: See Item 4 of the cover sheet for each reporting person.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 162828206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
(b)	Percent of class: Beryl: 0% Beryl GP: 0% Partnership: 0% David A. Witkin: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(ii) Shared power to vote or to direct the vote: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
	(iii) Sole power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A. Witkin: 0
	(iv) Shared power to dispose or to direct the disposition of: Beryl: 0 Beryl GP: 0 Partnership: 0 David A Witkin: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. Beryl is the investment adviser to the Partnership and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of the Partnership and other private investment funds. Mr. Witkin is the control person of Beryl.
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Beryl Capital Management LLC

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer
Date:	07/31/2025

Beryl Capital Management LP

Signature:	/s/ Andrew Nelson
Name/Title:	Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:	07/31/2025

Beryl Capital Partners II LP

Signature:	/s/ Andrew Nelson
Name/Title:	COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:	07/31/2025

David A. Witkin

Signature:	/s/ David A. Witkin
Name/Title:	Reporting person
Date:	07/31/2025

Exhibit Information

Exhibit 99.1 - Agreement Regrding Joint Filing of Statement on Schedule 13D or 13G

FAQ

What did Beryl Capital report about CKPT ownership?

The filing reports 0 beneficial shares and 0% of the class for Checkpoint Therapeutics common stock.

Who are the reporting persons in the Schedule 13G/A for CKPT?

The reporting persons are Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin.

Does the filing claim the securities were acquired to influence control of CKPT?

No. The certifications state the securities were not acquired and are not held to change or influence control of the issuer.

How much voting or dispositive power do the reporting persons have over CKPT shares?

The filing reports 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power for each reporting person.

Is the reported ownership more than 5% of CKPT?

No. Item 5 indicates ownership of 5 percent or less of the class; the reported percent is 0%.